<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03098173</url>
  </required_header>
  <id_info>
    <org_study_id>P2015034-11Y</org_study_id>
    <secondary_id>UMIN000021129</secondary_id>
    <nct_id>NCT03098173</nct_id>
  </id_info>
  <brief_title>Comparing Early Versus Elective Colonoscopy</brief_title>
  <official_title>A Multi-center, Randomized Controlled Trial Comparing Early Versus Elective Colonoscopy in Outpatients With Acute Lower Gastrointestinal Bleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tokyo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tokyo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-center, randomized controlled trial study is planned to include 162 outpatients
      with onset of acute lower gastrointestinal bleeding to compare the rate of identification of
      stigmata of recent hemorrhage (SRH), and other clinical outcomes, including the 30-day
      rebleeding rate, between 'early' colonoscopy and 'elective' colonoscopy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients will receive early colonoscopy or elective colonoscopy, but they do so by
      different timing.

      Early colonoscopy will be performed within 24 h of the initial visit. Elective colonoscopy
      will be performed between 24 and 96 h after the initial visit.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 29, 2016</start_date>
  <completion_date type="Anticipated">May 4, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel, randomized, superiority trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SRH identification rate</measure>
    <time_frame>0-4 day</time_frame>
    <description>SRH based on colonoscopic visualization of lesions, such as diverticulosis, tumor, ulcer, hemorrhoid, angioectasia, and polyps exhibiting active bleeding, a visible vessel, or an adherent clot.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Success rate of endoscopic treatment</measure>
    <time_frame>0-4 day</time_frame>
    <description>Success rate will be defined as the number achieving hemostasis per total number of attempts at endoscopic hemostasis during colonoscopy examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for additional endoscopic examinations</measure>
    <time_frame>0-34 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for interventional radiology</measure>
    <time_frame>0-34 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for surgery</measure>
    <time_frame>0-34 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thirty-day rebleeding rates</measure>
    <time_frame>30 day</time_frame>
    <description>Rebleeding will be defined as significant fresh blood loss after an initial colonoscopy with any of the following criteria:
i) Hemorrhagic shock, including cold sweat, nausea, syncope, or systolic blood pressure ≤ 90 mmHg.
ii) Need for transfusion, according to the guidelines of the Ministry of Health, Labour, and Welfare.
iii) Further colonoscopy identifies blood pooling, or iv) SRH in the lower gastrointestinal tract. v) Contrast-enhanced CT identifies extravasation in the colorectal region. However, these examinations will not be performed routinely if rebleeding occurs in the study period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for transfusion during hospitalization</measure>
    <time_frame>During hospitalization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>0-34 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thirty-day thrombosis events</measure>
    <time_frame>30 day</time_frame>
    <description>Thrombosis events will include acute coronary syndromes, including angina pectoris and myocardial infarction, stroke, including cerebrovascular infarction, cerebral hemorrhage, and transient ischemic attacks, deep vein thrombosis, and pulmonary embolism.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thirty-day mortality</measure>
    <time_frame>30 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preparation-related adverse events</measure>
    <time_frame>0-4 day</time_frame>
    <description>Preparation-related adverse events will include nausea, vomiting, abdominal pain, volume overload, aspiration pneumonia, hemorrhagic shock, exacerbation bleeding, and ileus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colonoscopy-related adverse events</measure>
    <time_frame>0-4 day</time_frame>
    <description>Colonoscopy-related adverse events will include hemorrhagic shock, and perforation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Acute Lower Gastrointestinal Bleeding</condition>
  <arm_group>
    <arm_group_label>Early colonoscopy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Performance of prepared colonoscopy within 24 h of arrival</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elective colonoscopy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Performance of prepared colonoscopy between 24 and 96 h after arrival</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Early colonoscopy</intervention_name>
    <description>Performance of prepared colonoscopy within 24 h of arrival</description>
    <arm_group_label>Early colonoscopy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Elective colonoscopy</intervention_name>
    <description>Performance of prepared colonoscopy between 24 and 96 h after arrival</description>
    <arm_group_label>Elective colonoscopy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females aged ≥ 20 years, presenting with moderate-to-severe hematochezia or
             melena within 24 h of arrival, defined as (i) more than three occurrences of
             hematochezia within 8 h, (ii) hemorrhagic shock, or (iii) requiring transfusion.

          2. Provision of signed and dated informed consent form.

          3. Stated willingness to comply with all study procedures and availability for the
             duration of the study.

        Exclusion Criteria:

        An individual who meets any of the following criteria will be excluded from participation
        in this study:

          1. Patients with hematemesis, black vomiting, or melena.

          2. Patients with upper gastrointestinal bleeding, diagnosed by nasogastric tube or upper
             endoscopy.

          3. Patients who have impossible consumed the oral bowel preparation solution.

          4. Patients who have undergone computed tomography.

          5. Patients who have been diagnosed with peptic ulcer diseases within the previous 10
             days.

          6. Ulcerative colitis or Crohn's disease patients.

          7. Patients who have undergone abdominal surgery within the previous 10 days.

          8. Patients who have undergone polypectomy, endoscopic mucosal resection, or endoscopic
             submucosal dissection of the lower gastrointestinal tract within the previous 10 days.

          9. Patients with suspected perforation or peritonitis.

         10. Patients with suspected intestinal obstruction.

         11. Patients with hemorrhagic shock refractory to infusion or blood transfusion.

         12. Patients who have undergone total colectomy.

         13. Patients with suspected disseminated intravascular coagulation.

         14. Patients with end-stage malignant disease.

         15. Patients with severe cardiac failure.

         16. Patients with active thrombosis.

         17. Patients with severe respiratory failure.

         18. Pregnant patients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Atsuo Yamada, MD</last_name>
    <role>Study Director</role>
    <affiliation>Tokyo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ryota Niikura, MD</last_name>
    <phone>+81-3-3815-5411</phone>
    <phone_ext>34717</phone_ext>
    <email>rniikura@triton.ocn.ne.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kazuo Hara, MD</last_name>
      <phone>+81-52-762-6111</phone>
      <email>khara@aichi-cc.jp</email>
    </contact>
    <investigator>
      <last_name>Kazuo Hara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hirosaki University Hospital</name>
      <address>
        <city>Hirosaki-shi</city>
        <state>Aomori</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatsuya Mikami, MD</last_name>
      <phone>+81-172-39-5053</phone>
      <email>tmika@hirosaki-u.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Center for Global Health and Medicine kohnodai hospital</name>
      <address>
        <city>Ichikawa-shi</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomoyuki Yada, MD</last_name>
      <phone>+81-47-372-3501</phone>
      <email>tomoyuki0618@yahoo.co.jp</email>
    </contact>
    <investigator>
      <last_name>Tomoyuki Yada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fukui prefectural hospital</name>
      <address>
        <city>Fukui-shi</city>
        <state>Fukui</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenkei Hasatani, MD</last_name>
      <phone>+81-776-54-5151</phone>
      <email>hasatani9@yahoo.co.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Hakodate Hospital</name>
      <address>
        <city>Hakodate-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katsuhiro Mabe, MD</last_name>
      <phone>+81-138-51-6281</phone>
      <email>kmabe@hnh.hosp.go.jp</email>
    </contact>
    <investigator>
      <last_name>Katsuhiro Mabe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Otaru Ekisaikai Hospital</name>
      <address>
        <city>Otaru-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomoki Fujita, MD</last_name>
      <phone>+81-134-24-0325</phone>
      <email>tomoki-fujita@otaru-ekisaikai.jp</email>
    </contact>
    <investigator>
      <last_name>Tomoki Fujita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tonan Hospital</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tetsuya Sumiyoshi, MD</last_name>
      <phone>+81-11-231-2121</phone>
      <email>t-sumiyoshi@tonan.gr.jp</email>
    </contact>
    <investigator>
      <last_name>Tetsuya Sumiyoshi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ishikawa prefectural central hospital</name>
      <address>
        <city>Kanazawa city</city>
        <state>Ishikawa</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hisashi Doyama, MD</last_name>
      <phone>+81-76-237-8211</phone>
      <email>doyama.134@ipch.jp</email>
    </contact>
    <investigator>
      <last_name>Hisashi Doyama, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nagasaki Harbor Medical Center City Hospital</name>
      <address>
        <city>Nagasaki-shi</city>
        <state>Nagasaki</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tetsuro Honda, MD</last_name>
      <phone>+81-95-822-3251</phone>
      <email>tetsupeacevo@yahoo.co.jp</email>
    </contact>
    <investigator>
      <last_name>Tetsuro Honda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Japan Community Healthcare Organization Osaka Hospital</name>
      <address>
        <city>Fukushima-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katsumi Yamamoto, MD</last_name>
      <phone>+81-6-6441-5451</phone>
      <email>katsumiy770@yahoo.co.jp</email>
    </contact>
    <investigator>
      <last_name>Katsumi Yamamoto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toyonaka Municipal Hospital</name>
      <address>
        <city>Toyonaka-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tsutomu Nishida, MD</last_name>
      <phone>+81-6-6843-0101</phone>
      <email>tnishida.gastro@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Tsutomu Nishida, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Tokyo</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atsuo Yamada, MD</last_name>
      <phone>+81-3-3815-5411</phone>
      <email>yamada-a@umin.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Atsuo Yamada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ryota Niikura, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's International Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naoki Ishii, MD</last_name>
      <phone>+81-3-3541-5151</phone>
      <email>naoishi@luke.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Naoki Ishii</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Center for Global Health and Medicine center hospital</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naoyoshi Nagata, MD</last_name>
      <phone>+81-3-3202-7181</phone>
      <email>nnagata_ncgm@yahoo.co.jp</email>
    </contact>
    <investigator>
      <last_name>Naoyoshi Nagata, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shuto General Hospital</name>
      <address>
        <city>Yanai-shi</city>
        <state>Yamaguchi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shu Kiyotoki, MD</last_name>
      <phone>+81-820-22-3456</phone>
      <email>shu2026eb@hi.enjoy.ne.jp</email>
    </contact>
    <investigator>
      <last_name>Shu Kiyotoki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.todai-shoukakan.com/cont4/29.html</url>
    <description>Early versus Elective Colonoscopy Trial</description>
  </link>
  <reference>
    <citation>Niikura R, Nagata N, Doyama H, Ota R, Ishii N, Mabe K, Nishida T, Hikichi T, Sumiyama K, Nishikawa J, Uraoka T, Kiyotoki S, Fujishiro M, Koike K. Current state of practice for colonic diverticular bleeding in 37 hospitals in Japan: A multicenter questionnaire study. World J Gastrointest Endosc. 2016 Dec 16;8(20):785-794. doi: 10.4253/wjge.v8.i20.785.</citation>
    <PMID>28042393</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2017</study_first_submitted>
  <study_first_submitted_qc>March 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2017</study_first_posted>
  <last_update_submitted>June 5, 2017</last_update_submitted>
  <last_update_submitted_qc>June 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tokyo University</investigator_affiliation>
    <investigator_full_name>Atsuo Yamada</investigator_full_name>
    <investigator_title>Department of Gastroenterology</investigator_title>
  </responsible_party>
  <keyword>Early colonoscopy</keyword>
  <keyword>Stigmata of recent hemorrhage</keyword>
  <keyword>Rebleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Gastrointestinal Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://www.todai-shoukakan.com/cont4/29.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

